|Bid||116.10 x 100|
|Ask||118.99 x 100|
|Day's Range||117.85 - 121.30|
|52 Week Range||61.45 - 125.86|
|PE Ratio (TTM)||35.73|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||3.84 (3.24%)|
|1y Target Est||125.85|
Voyager continued rocketing Wednesday after announcing a collaboration with AbbVie to develop an Alzheimer's disease drug.
AbbVie (NYSE:ABBV) and Voyager Therapeutics, Inc. (NASDAQ:VYGR) are big movers in the biotechnology space during the middle of this week, with the two companies putting out some potentially game-changing news (and the news is interrelated – more on this shortly) and picking up some action in their market capitalization on the back of the development. […] The post Here’s What The AbbVie and Voyager Therapeutics Deal Really Means appeared first on Market Exclusive.
AbbVie Inc. and Neurocrine Biosciences Inc. shares rose 1.7% and 1.1% respectively in premarket trade Wednesday after the companies announced that their drug met its primary endpoint in a phase 3 trial ...
Canadians living with Moderate to Severe Hidradenitis Suppurativa are beginning to have public access to HUMIRA® (Adalimumab) to manage their disease
− First of two pivotal Phase 3 studies met primary efficacy endpoint and all ranked secondary endpoints − Results demonstrated elagolix, in combination with low-dose add-back therapy, reduced heavy menstrual ...
A trial under way in federal court in Philadelphia is testing the power of U.S. competition regulators to crack down on drug makers’ alleged moves to thwart the sale of low-cost generics.
Voyager Therapeutics said Tuesday that it will work with AbbVie to develop gene therapy treatments for Alzheimer’s disease in a deal worth at least $69 million for the Cambridge biotech. The announcement by Voyager (VYGR) and Chicago-based AbbVie (ABBV) comes as drug developers are exploring new approaches to Alzheimer’s following a string of recent clinical setbacks. Gene therapies — drugs that work by inserting healthy genes into a person’s cells to replace faulty or missing ones — offer one intriguing avenue.
Your stocks to watch: Five names with high relative strength lines: Netflix, Ferrari, Adobe, AbbVie and Weight Watchers. Strong in the correction, booming now.
Collaboration to include development of gene therapies consisting of vectors to deliver monoclonal antibodies to the brain directed against tau. Voyager to receive $69 million upfront payment and potentially ...
NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Feb. 20, 2018 /PRNewswire/ -- AbbVie (ABBV), a global biopharmaceutical company, and Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company, today announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases. This collaboration combines AbbVie's monoclonal antibody expertise, global clinical development and commercial capabilities with Voyager's gene therapy platform and expertise that enables generating adeno-associated viral (AAV) vectors for the treatment of neurodegenerative diseases.
A pair of top-shelf tech companies, and the maker of the world's most popular pharmaceutical, recently announced increases in their quarterly payouts.
AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.
Novartis: What Are the Major Growth Drivers for 2018? On November 6, 2017, Novartis (NVS) announced positive data from the MEASURE 1 trial, which highlighted the potential of Cosentyx in preventing the progression of disease in the majority of the patients with ankylosing spondylitis. According to the Arthritis Foundation, “Spondyloarthritis is an umbrella term for inflammatory diseases that involve both the joints and the entheses (the sites where the ligaments and tendons attach to the bones).
- At week 16, 37 and 51 percent of patients with plaque psoriasis treated with risankizumab achieved clear skin (sPGA 0) compared to STELARA® (ustekinumab) (14 and 25 percent)(1) - At one year (52 weeks), ...
- Upadacitinib showed a reduction in itch (pruritus) as early as Week 1(1) - Upadacitinib also showed improvement in the extent and severity of skin lesions at Week 2 for all doses(1) - Safety profile ...
Marijuana stocks are still in their infancy, meaning there's a whole host of weed-adjacent stock moves waiting to be made. Here are the best bets.
Moody's Investors Service commented that higher shareholder payouts by AbbVie Inc. ("AbbVie") are credit negative. There is no impact on AbbVie's ratings including the Baa2/Prime-2 ratings or ...
Novartis: What Are the Major Growth Drivers for 2018? On November 14, 2016, Novartis (NVS) announced positive results from the Phase 3 pivotal study, FUTURE 1. This study highlighted the efficacy of Cosentyx in providing sustained benefit over three years in psoriatic arthritis patients.
AbbVie Inc (NYSE:ABBV) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Novartis: What Are the Major Growth Drivers for 2018? On January 16, 2018, Novartis (NVS) released data from its Phase 3b trial, CLARITY. This release highlighted the superiority of Cosentyx compared to Johnson & Johnson’s (JNJ) Stelara in clearing skin in patients with moderate to severe psoriasis at the end of 12 weeks and 16 weeks of therapy.
Novartis: What Are the Major Growth Drivers for 2018? In 4Q17, Novartis’s (NVS) Cosentyx reported global sales of $615.0 million, which is a year-over-year (or YoY) increase of 53.0% on a constant currency basis and 11.0% growth quarter-over-quarter. This growth was driven by the drug’s rapid uptake in all approved indications and in all geographies, with a focus on the US and Europe.